viewAnteris Technologies Ltd

Anteris Technologies comparison study shows ADAPT® treated tissue has superior anti-calcification attributes

Proven benefits of the ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to challenges facing heart surgeons.

Anteris Technologies Ltd - Anteris Technologies delivers 40% less calcium concentration in anti-calcification study for ADAPT® treated tissue
Anteris is a structural heart company delivering clinically superior and durable solutions through better science and better design

Anteris Technologies Ltd’s (ASX:AVR) (OTCMKTS:AMEUF) anti-calcification comparison study demonstrates that the company's ADAPT® treated tissue has superior anti-calcification attributes compared with tissues used in competitor valves.

Results at the half-way point of four months showed ADAPT®  – used in their game-changing DurAVR™ 3D single-piece aortic valve – had approximately 40% less calcium concentration compared with the Medtronic AOA™ arm – tissue used in commercially available SAVR (surgical aortic valve replacement) and TAVR (transcatheter aortic valve replacement) valves.

The interim results correlated with existing clinical data and those of the prior head-to-head study with a similar protocol which produced significant differentials between ADAPT® tissue and Edwards Life Sciences’ Thermafix tissue at the eight to 12-month mark.

Highly positive results 

Anteris chief executive officer Wayne Paterson said: “The results were highly positive for ADAPT®, indicating our ADAPT® anti-calcification treatment is statistically superior to both of the major competitors.

“Whilst we have long understood the clinical superiority of ADAPT®, it’s critical for the regulatory submission to prove this against market incumbents specifically in the TAVR space.”

Samples implanted

A total of 48 juvenile rats were implanted with four different samples into separate subcutaneous pockets for calcification evaluation of the following tissues:

  • ADAPT®-treated bovine pericardium;
  • AOA™-treated porcine tissue;
  • AOA™-treated bovine tissue; and
  • Control (Glutaraldehyde-treated bovine pericardium).

The final results of the eight-month study will be used in the US Food and Drug Administration submissions to demonstrate DurAVR™ superiority compared with currently available valves subject to the final results being consistent with these positive interim results.

Shares have been almost 5% higher to A$3.84 intra-day.

Quick facts: Anteris Technologies Ltd

Price: 5.03 AUD

Market: ASX
Market Cap: $31.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read